Claims for Patent: 4,762,707

Summary for Patent: 4,762,707

Title:	New conjugates associating, by covalent bond, an enzyme with an antibody, and medicinal associations using the said conjugates
Abstract:	The present invention relates to new immunoenzymic conjugates resulting from a chemical coupling, by covalent bond, of an antibody or a fragment of antibody, which has retained the capacity of recognizing the selected antigen, with an enzyme capable of producing ammonium ions from natural substrates which are well tolerated in higher animal organisms. The invention also relates to a process for the preparation of these conjugates and the medicinal associations of said conjugates with an immunotoxin.
Inventor(s):	Jansen; Franz (St. Mathieu De Treviers, FR), Gros; Pierre (Montpellier, FR)
Assignee:	Sanofi (Societe Anonyme) (Paris, FR)
Application Number:	06/736,334
Patent Claims:	1. An immunoenzymic conjugate comprising an antibody or a fragment thereof having the capacity to recognize a specific antigen, covalently bonded to an enzyme capable of producing ammonium ions from natural substrates well tolerated in higher animal organisms. 2. A conjugate as claimed in claim 1 wherein the covalent bond is a disulfide bond. 3. A conjugate as claimed in claim 1, wherein the covalent bond is a thioether bond. 4. A conjugate as claimed in claim 1, wherein the enzyme covalently bonded to the antibody or fragment thereof, is selected from the group consisting of a sub-group 1-4 containing amino-acids-dehydrogenase and amino-oxydase, a sub-group 3-5 enzyme comprising the enzymes hydrolizing amines, amidines, and other C--N nonpeptidic bonds, a sub-group 4-2 and 4-3 enzyme catalyzing degradation reactions with formation of nonsaturated compounds. 5. A conjugate as claimed in claims 4 wherein the enzyme covalently bonded to the antibody or a fragment thereof, is 1-4-1-1:alanine dehydrogenase, 1-4-1-3:glutamate dehydrogenase NAD (P).sup.+, 1-4-1-5:L-amino-acids dehydrogenase, 1-4-3-2:L-amino-acids oxydase, 3-5-1-1:asparaginase, 3-5-1-2:glutaminase, 3-5-1-4:amidase, adenosine deaminase, 3-5-4-66:adenosine monophosphate deaminase, 3-5-4-21:creatinine deaminase, 4-2-1-13:L-serine dehydratase, 4-2-1-16:L-threomine dehydratase, 4-3-1-1:aspartate-ammonia-lyase, 4-3-1-3:histidine-ammonia-lyase or 4-3-1-5:phenylalanine-ammonia-lyase. 6. A conjugate as claimed in claim 5 wherein the covalent bond is a disulfide bond. 7. A conjugate as claimed in claim 5 wherein the covalent bond is a thioether bond. 8. A pharmaceutical composition comprising a therapeutically effective amount of at least one immunotoxin formed between the A chain of ricin and an antibody or an antibody fragment and a potentiating amount of at least one immunoenzymic conjugate as claimed in claim 1, and an pharmaceutically acceptable carrier. 9. A pharmaceutical composition as claimed in claim 8 in injectible form. 10. A method of potentiating an immunotoxin formed between the A-chain of ricin and an antibody or an antibody fragment, at the immediate environment of a mammalian target-cell for said immunotoxin, which comprises administering a potentiating effective amount of the immunoenzymic conjugate of claim 1 to a patient having target-cells, to cause reaction of said immunoenzymic conjugate with a natural substrate located in the area of the target-cells to generate a potentiating amount of ammonium ions for said immunotoxin. 11. A method of potentiating an immunotoxin formed between the A-chain of ricin and an antibody or an antibody fragment; at the immediate environment of a mammalian target-cell for said immunotoxin, which comprises administering a potentiating effecting amount of the immunoenzymic conjugate of claim 1 to a patient having target-cells for said immunotoxin, and wherein a substrate for the enzyme of the immunoenzyme conjugate is not present in the blood and the extra cellular liquid in a high enough concentration to effect a potentiating reaction between the substrate and the immunoenzymic conjugate, and administering an effective amount of a substrate to the patient being treated with the immunotoxin and immunoenzymic conjugate to cause reaction of said immunoenzymic conjugate with the substrate located in the area of the target-cells to generate a potentiating amount of ammonium ions for said immunotoxin.

Details for Patent 4,762,707

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2005-08-09